TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04848519

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO for patients on the ICI plus propranolol arm

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection

Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
Study: NCT06532526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)
Description: A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)
Description: Fluoride gel that applied on the teeth to reduce tooth sensitivity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel without any active ingredients.
Description: Water-based glycerin gel is used as the Placebo gel without active ingredients
Study: NCT05478512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VenObi+Ven or VenObi+VenZan
Description: Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression
Study: NCT04743297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2 (Propess)
Description: Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2 (Prostin)
Description: Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
Study: NCT06348602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution 0.1%
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
Study: NCT04207424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emblization of the gastro-epiploic arcade
Description: Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
Study: NCT06015308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Subcutaneous injection in abdomen, outer thigh, or upper arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection in abdomen, outer thigh, or upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Description: Intramuscular (IM) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tdap vaccine
Description: Intramuscular (IM) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPS vaccine
Description: Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PPS vaccine
Description: Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
Study: NCT05728645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg
Description: Intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Electrolytes injection of 5 ml/kg
Description: Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
Study: NCT03904069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 553
Description: AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
Study: NCT05018312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Collaborative Assessment (MCA)
Description: The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment as Usual (AAU)
Description: Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
Study: NCT04693702

Intervention type: DEVICE
Intervention: Corneal treatment by a low vision aid device
Description: Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.

Intervention type: DEVICE
Intervention: Corneal treatment by a low vision aid device
Description: Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
Study: NCT04974905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: retrograde access for re-canalization of infra-inguinal arterial occlusive disease
Description: after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
Study: NCT06341114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 injection
Description: BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 injection
Description: One vial of 4 mL of concentrate contains 100 mg of BAT1308
Study: NCT06409936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: both arms will include asciminib treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: both arms will include asciminib treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: in the arm B the nilotinib will be added on in all patients
Study: NCT05731817

Intervention type: OTHER
Intervention: Observational study
Description: N/A - observational study.
Study: NCT06576674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber + Green Tea Extract
Description: 10g fiber + 750mg green tea supplement will be administered at experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber + Green Tea Extract
Description: 10g fiber + 750mg green tea supplement will be administered at experimental arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: alcohol administered up to a target BAC 60mg% during lab sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: alcohol administered up to a target BAC 60mg% during lab sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame Placebo Supplement
Description: Aspartame sweetener mixed with water + aspartame capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame Placebo Supplement
Description: Aspartame sweetener mixed with water + aspartame capsule
Study: NCT04813614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE M Lidocaine
Description: Injection in the lips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Injection in the lips
Study: NCT06360055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-mannose
Description: Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
Study: NCT06348602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ophthalmic ointment 0.03%
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
Study: NCT05422846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise protocol
Description: The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
Study: NCT06300151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia
Description: Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural Labor Analgesia
Description: Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
Study: NCT05243524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maveropepimut-S
Description: SC injection on days 7, 28, then q8w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: PO BID, one week on, one week off
Study: NCT05193201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin injection
Description: recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin injection
Description: recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Study: NCT06230549

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
Study: NCT05829447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE 760 R endoscope
Description: The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
Study: NCT06501547

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Leucocyte Telomere Length from blood draw
Description: blood draw, PCR method to see leucocyte telomere length

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Leucocyte Telomere Length from blood draw
Description: blood draw, PCR method to see leucocyte telomere length
Study: NCT05994924

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Handout
Description: Educational handout describing responsive feeding practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Series
Description: Videos geared toward responsive feeding practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Series
Description: Videos geared toward responsive feeding practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Discussion Sessions
Description: Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
Study: NCT05171309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg intravenously every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cell
Description: Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
Study: NCT05948059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2106 injection or placebo
Description: starting dose from 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2106 injection or placebo
Description: starting dose from 300 mg
Study: NCT05282966

Intervention type: DIAGNOSTIC_TEST
Intervention: QSant-TM Urine Test
Description: QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
Study: NCT04737291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: use of drug coated balloon in treatment of critical limb ischemia
Study: NCT06368544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lower-body positive-pressure
Description: By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
Study: NCT06100198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition and exercise program
Description: Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
Study: NCT04959669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DeSSBack
Description: The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
Study: NCT06308406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab； HRS-1167
Description: Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
Study: NCT04881409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support with nasal high-flow (NHF)
Description: Patient with AECOPD is treated with NHF.
Study: NCT05985577

Intervention type: OTHER
Intervention: Without any intervention
Description: There were no special interventions for the two groups.

Intervention type: OTHER
Intervention: Without any intervention
Description: There were no special interventions for the two groups.
Study: NCT04550832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
Study: NCT05530863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Therapy
Description: The participant will receive coaching calls and support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: Standard Sleep Hygiene instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Standard Sleep Hygiene instructions.
Study: NCT06080464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VERABAND information
Description: The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
Study: NCT04771299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cariprazine
Description: Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.